Neuromod closes €30m financing for new tinnitus treatment device
April 14, 2023Sales and Marketing
Irish medical device company Neuromod has announced that it has successfully closed a €30m financing intended to further commercialise Lenire, …
Diabeloop announces collaboration with Novo Nordisk for connected diabetes treatment
April 14, 2023Research and Development
Automated insulin delivery company Diabeloop has announced its collaboration with global healthcare company Novo Nordisk, with an agreement which covers …
Merck’s relapsing multiple sclerosis trial put on FDA partial clinical hold over liver injuries
April 14, 2023Research and Development
Merck has announced that its clinical phase 3 study EVOLUTION has been put on partial clinical hold by the FDA …
FDA declines Eli Lilly’s bowel disease drug over manufacturing issues
April 14, 2023Manufacturing and Production
Pharma giant Eli Lilly’s Biologic Licence Application (BLA) for its bowel disease drug has been declined by the FDA over …
UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal
April 13, 2023Business Services
Brussels (Belgium) 13 April 2023 – 07:00 AM (CET) – UCB, a global biopharmaceutical company, today announced that The Lancet Neurology …
Adaptyv Bio creates a new paradigm for protein engineering using generative AI, open-source software and synthetic biology
April 13, 2023Business Services
Lausanne, Switzerland – 13th April 2023; AI tools like ChatGPT are revolutionizing how the world generates text, images and code. …
BioInnovation Institute & Science Prize for Innovation winners announced
April 13, 2023Business Services
COPENHAGEN, Denmark, April 13, 2023 – BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, …
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 13, 2023Sales and Marketing
Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …
ANGLE plc (“the Company”) Pharma Services Contract with Crescendo Biologics
April 13, 2023Business Services
ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has signed a …
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
April 13, 2023Business Services
Strasbourg, France, April 12, 2023, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops …
Alentis Therapeutics closes $105m Series C funding for new treatment options
April 13, 2023Sales and Marketing
Alentis Therapeutics has announced $105m in Series C funding which was led by Jeito Capital together with Novo Holdings A/S …
Biogen announces licensing of Denali’s ATV to target Amyloid Beta
April 13, 2023Research and Development
Biogen and Denali Therapeutics have announced that Biogen has exercised its option to license Denali’s Antibody Transport Vehicle: Amyloid beta …
Aspect Biosystems and Novo Nordisk partner with $75m deal to develop bioprinted tissue therapeutics
April 13, 2023Research and Development
Canadian biotech company Aspect Biosystems and Denmark-based Novo Nordisk have announced a collaboration, development and license agreement to develop bioprinted …
Kala Pharmaceuticals receives FDA Fast Track Designation for human MSC-S therapy
April 13, 2023Medical Communications
Clinical-stage biopharmaceutical company Kala Pharmaceuticals has announced that the FDA has granted it Fast Track Designation for its human mesenchymal …
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) ACCEPTED FOR USE WITHIN NHS SCOTLAND EARLIER IN THE TREATMENT PATHWAY FOR HER2-POSITIVE METASTATIC BREAST CANCER
April 12, 2023Business Services
Daiichi Sankyo UK Limited and AstraZeneca UK Limited welcome the news that the Scottish Medicines Consortium (SMC) has accepted Enhertu®▼ …
Almirall, the first to assess wellbeing in a dermatology clinical study
April 12, 2023Business Services
BARCELONA, Spain. April 12, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced the …
Liberal states begin stockpiling abortion medications following Texas court ruling
April 12, 2023Medical Communications
Various liberal US states, including California and Massachusetts, have begun stockpiling abortion medications following a Texas judge Matthew Kacsmaryk’s attempt …
Moderna announces mixed success clinical updates for mRNA pipeline
April 12, 2023Research and Development
Biotechnology company Moderna has announced clinical updates detailing the expansion and advancement of its mRNA pipeline, which includes treatments for …
ImaginAb signs new license and supply agreement with Leucid Bio for CD8 ImmunoPET technology
April 12, 2023Sales and Marketing
Biotechnology company ImaginAb has announced that it has signed a new non-exclusive License and Supply Agreement (LSA) with Leucid Bio. …
Cognizant and Boehringer Ingelheim collaborate on integrated cloud platform to improve therapy development
April 12, 2023Medical Communications
US-based Cognizant and biopharmaceutical company Boehringer Ingelheim have announced a partnership to collaborate on ensuring the quality, and increasing the …
